Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Biogen pays $125 million upfront for rights to InnoCare's orelabrutinib in MS deal

firstwordpharmaJuly 13, 2021

Tag: Biogen , InnoCare , Orelabrutinib

PharmaSources Customer Service